Key Takeaways Amneal Pharmaceuticals trades at 1.39x sales, below industry and sector averages.AMRX shares surged 83% in a year, but paused as 2026 Specialty growth slows.AMRX targets $14 on 1.5x sales, tied to launches, margins, and execution.Amneal Pharmaceuticals (AMRX) has built momentum on broad-based growth across generics, Specialty, and its government-focused distribution business. Results in 2025 showed higher revenues, higher earnings, and expanding cash generation, supported by mix improvement an ...